Sharekhan has come out with its second quarter (July-September’ 18) earnings estimates for the Pharma sector. The brokerage house expects Cadila to report net profit at Rs. 386 crore down 23.3% year-on-year (up 9% quarter-on-quarter).
Net Sales are expected to decrease by 4.4 percent Y-o-Y (up 8.1 percent Q-o-Q) to Rs. 3,093 crore, according to Sharekhan.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
